Skip to main content
. 2019 Aug 5;10(8):581. doi: 10.1038/s41419-019-1815-7

Fig. 6. The PRMT3 inhibitor SGC707 inhibits osteogenic differentiation of MSCs.

Fig. 6

a, b ALP staining (a) and quantification (b) indicated that SGC707 treatment attenuated ALP activity in MSCs at 7 days after osteogenic induction. Data are shown as mean ± SD; n = 3; *P < 0.05 compared with vehicle (0 μM), **P < 0.01 compared with vehicle (0 μM) by ANOVA with Tukey’s post hoc test. c, d Alizarin Red Staining (c) and quantification (d) of MSCs following SGC707 treatment at 14 days after osteogenic induction. Data are shown as mean ± SD; n = 3; *P < 0.05 compared with vehicle (0 μM); **P < 0.01 compared with vehicle (0 μM) by ANOVA with Tukey’s post hoc test. e–g qRT-PCR analysis of mRNA expression levels of the osteogenesis-related genes RUNX2 (e), SP7 (f), and ALP (g) in MSCs at 7 days after osteogenic induction. Data are shown as mean ± SD; n = 3; *P < 0.05 compared with vehicle (0 μM); **P < 0.01 compared with vehicle (0 μM) by ANOVA with Tukey’s post hoc test. h, i The in vivo bone formation experiment. H&E staining (h) and IHC staining (i) for OCN of groups with or without treatment of SGC707. Scale bar: 50 μm. Black arrows indicate positive staining of OCN